The Moderating Role of Genetics on the Effectiveness of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) Program on Cognitive Impairment

Abstract

Background

Genetics may influence symptoms experienced by breast cancer survivors (BCS) by moderating the effects of stress-reducing interventions, including the Mindfulness-Based Stress Reduction (MBSR(BC)) program, to reduce symptom severity. As part of a larger clinical trial, the aim of this study was to evaluate genetic variants as moderators of MBSR(BC) on improvements among BCS in cognitive functioning and symptoms.

Methods

BCS (n = 128) were randomized to MBSR(BC) or the Breast Cancer Education Support Program. Objective neuropsychological and subjective measures of cognitive performance, and psychological and physical symptoms were collected at baseline, 6, 12, and 26 weeks. Linear mixed models were implemented to identify MBSR(BC)’s effects over time. A total of 22 single nucleotide polymorphisms (SNPs) from 20 genes known to be related to these symptoms were investigated using genomic DNA. These SNPs were tested as moderators of MBSR(BC) program effects.

Results

Results showed MBSR(BC) participants experienced significantly greater benefits in cognitive functioning, however, the level of benefit varied based on one’s genetic profile. Effects sizes, consistency across similar measures were investigated. Among 22 candidate SNPs, rs4680 in COMT, rs1800497 in ANKK1, and rs6277 in DRD2 demonstrated the strongest, most consistent positive effects in moderating MBSR(BC)’s impact on cognitive outcomes.

Conclusions

Although the effects were small, this translational research may potentially identify BCS with genotypes that would be most influenced by the MBSR(BC) program. These results may be used to develop personalized intervention programs tailored to the genetic profile of each breast cancer survivor who received chemotherapy or chemotherapy and radiation.

Trial Registration

ClinicalTrials.gov, https://www.ClinicalTrials.gov Registration Number: NCT02786797.

Keywords

breast cancer mindfulness-based stress reduction (MBSR)genetics cognitive function

Get full access to this article

View all access options for this article.

References

Aaronson

N. K.

Ahmedzai

Bergman

Bullinger

Cull

Duez

N. J.

Filiberti

Flechtner

Fleishman

S. B.

de Haes

J. C.

(1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365

American Cancer Society . (2019). Breast cancer facts & figures 2019-2020. 2019. https://www.cancer.org/

Andrews

S. J.

Das

Anstey

K. J.

Easteal

(2017). Association of AKAP6 and MIR2113 with cognitive performance in a population-based sample of older adults. Genes, Brain and Behavior, 16(4), 472–478. https://doi.org/10.1111/gbb.12368

Angelakopoulou

Shah

Sofat

Shah

Berry

D. J.

Cooper

Palmen

Tzoulaki

Wong

Jefferis

B. J.

Maniatis

Drenos

Gigante

Hardy

Laxton

R. C.

Leander

Motterle

Simpson

I. A.

Smeeth

Hingorani

A. D.

(2012). Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. European Heart Journal, 33(3), 393–407. https://doi.org/10.1093/eurheartj/ehr225

Benedict

(1997). Brief visuo-spatial memory test-revised (BVMT-R). Psychological Assessment Resources.

Benedict

R. H. B.

Schretlen

Groninger

Brandt

(1998). Hopkins verbal learning test revised: Normative data and analysis of inter-form and test-retest reliability. Clinical Neuropsychologist, 12(1), 43–55. https://doi.org/10.1076/clin.12.1.43.1726

Benton

Hamsher

(1989). Multilingual aphasia examination. https://www4.parinc.com/Default.aspx

Biegler

K. A.

Chaoul

M. A.

Cohen

(2009). Cancer, cognitive impairment, and meditation. Acta Oncologica, 48(1), 18–26. https://doi.org/10.1080/02841860802415535

Boykoff

Moieni

Subramanian

S. K.

(2009). Confronting chemobrain: An in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv, 3(4), 223–232. https://doi.org/10.1007/s11764-009-0098-x

10.

Cacabelos

(2007). Molecular pathology and pharmacogenomics in alzheimer's disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods & Findings in Experimental & Clinical Pharmacology, 29(Suppl A), 1–91.

11.

Corporation

T. P.

(2001). Wechsler test of adult reading. Harcourt Assessment.

12.

Davies

Marioni

R. E.

Liewald

D. C.

Hill

W. D.

Hagenaars

S. P.

Harris

S. E.

Ritchie

S. J.

Luciano

Fawns-Ritchie

Lyall

Cullen

Cox

S. R.

Hayward

Porteous

D. J.

Evans

McIntosh

A. M.

Gallacher

Craddock

Pell

J. P.

Deary

I. J.

(2016). Genome-wide association study of cognitive functions and educational attainment in UK Biobank (N = 112 151). Molecular Psychiatry, 21(6), 758–767. https://doi.org/10.1038/mp.2016.45

13.

Egan

M. F.

Goldberg

T. E.

Kolachana

B. S.

Callicott

J. H.

Mazzanti

C. M.

Straub

R. E.

Goldman

Weinberger

D. R.

(2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the U S A, 98(12), 6917–6922. https://doi.org/10.1073/pnas.111134598

14.

Ferguson

R. J.

Ahles

T. A.

Saykin

A. J.

McDonald

B. C.

Furstenberg

C. T.

Cole

B. F.

Mott

L. A.

(2007). Cognitive-behavioral management of chemotherapy-related cognitive change. Psycho-Oncology, 16(8), 772–777. https://doi.org/10.1002/pon.1133

15.

Ganz

P. A.

(2012). Doctor, will the treatment you are recommending cause chemobrain? Journal of Clinical Oncology, 30(3), 229–231. https://doi.org/10.1200/JCO.2011.39.4288

16.

Grady

P. A.

Gough

L. L.

(2015). Nursing science: Claiming the future. Journal of Nursing Scholarship, 47(6), 512–521. https://doi.org/10.1111/jnu.12170

17.

Hajj

Khoury

Hachem

Awad

Hallit

Sacre

Nasr

Karak

F. E.

Chahine

Kattan

Khabbaz

L. R.

(2022). Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: The “CAGE-Cog” study. BMC Cancer, 22(1), 996. https://doi.org/10.1186/s12885-022-10077-6

18.

Hashizume

Nakano

Kubota

Sato

Himuro

Kobayashi

Takaoka

Fujimiya

(2021). Mindfulness intervention improves cognitive function in older adults by enhancing the level of miRNA-29c in neuron-derived extracellular vesicles. Scientific Reports, 11(1), 21848. https://doi.org/10.1038/s41598-021-01318-y

19.

Yang

Gao

Fan

Feng

(2016). Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: A PRISMA compliant meta-analysis. Neuropsychiatric Disease and Treatment, 12, 3129–3144. https://doi.org/10.2147/NDT.S118614

20.

Hou

Q. F.

S. B.

(2009). Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neuroscience Letters, 464(2), 127–130. https://doi.org/10.1016/j.neulet.2009.08.004

21.

Wang

(2019). The roles of ANRIL polymorphisms in coronary artery disease: A meta-analysis. Bioscience Reports, 39(12), BSR20181559. https://doi.org/10.1042/BSR20181559

22.

Janelsins

M. C.

Heckler

C. E.

Peppone

L. J.

Kamen

Mustian

K. M.

Mohile

S. G.

Magnuson

Kleckner

I. R.

Guido

J. J.

Young

K. L.

Conlin

A. K.

Weiselberg

L. R.

Mitchell

J. W.

Ambrosone

C. A.

Ahles

T. A.

Morrow

G. R.

(2017). Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. Journal of Clinical Oncology, 35(5), 506–514. https://doi.org/10.1200/JCO.2016.68.5826

23.

Jensen

M. C.

Keegan

T. H.

(2016). The Measuring Your Health study: Leveraging community-based cancer registry recruitment to establish a large, diverse cohort of cancer survivors for analyses of measurement equivalence and validity of the Patient Reported Outcomes Measurement Information System®(PROMIS®) short form items. Psychol Test Assess Model, 58(1), 99.

24.

Johns

S. A.

Von Ah

Brown

L. F.

Beck-Coon

Talib

T. L.

Alyea

J. M.

Monahan

P. O.

Tong

Wilhelm

Giesler

R. B.

(2016). Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: Effects on cancer-related cognitive impairment. J Cancer Surviv, 10(3), 437–448. https://doi.org/10.1007/s11764-015-0494-3

25.

Lengacher

C. A.

Johnson-Mallard

Post-White

Moscoso

M. S.

Jacobsen

P. B.

Klein

T. W.

Widen

R. H.

Fitzgerald

S. G.

Shelton

M. M.

Barta

Goodman

Cox

C. E.

Kip

K. E.

(2009). Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psycho-Oncology, 18(12), 1261–1272. https://doi.org/10.1002/pon.1529

26.

Lengacher

C. A.

Reich

R. R.

Kip

K. E.

Paterson

C. L.

Park

H. Y.

Ramesar

Jim

H. S. L.

Alinat

C. B.

Park

J. Y.

(2015a). Moderating effects of genetic polymorphisms on improvements in cognitive impairment in breast cancer survivors participating in a 6-week mindfulness-based stress reduction program. Biological Research For Nursing, 17(4), 393–404. https://doi.org/10.1177/1099800415577633

27.

Lengacher

C. A.

Reich

R. R.

Paterson

C. L.

Jim

H. S.

Ramesar

Alinat

C. B.

Budhrani

P. H.

Farias

J. R.

Shelton

M. M.

Moscoso

M. S.

Park

J. Y.

Kip

K. E.

(2015b). The effects of mindfulness-based stress reduction on objective and subjective sleep parameters in women with breast cancer: A randomized controlled trial. Psycho-Oncology, 24(4), 424–432. https://doi.org/10.1002/pon.3603

28.

Lengacher

C. A.

Reich

R. R.

Paterson

C. L.

Ramesar

Park

J. Y.

Alinat

Johnson-Mallard

Moscoso

Budhrani-Shani

Miladinovic

Jacobsen

P. B.

Cox

C. E.

Goodman

Kip

K. E.

(2016). Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: A randomized controlled trial. Journal of Clinical Oncology, 34(24), 2827–2834. https://doi.org/10.1200/JCO.2015.65.7874

29.

Lengacher

C. A.

Reich

R. R.

Ramesar

Alinat

C. B.

Moscoso

Cousin

Marino

V. R.

Elias

M. N.

Paterson

C. L.

Pleasant

M. L.

Rodriguez

C. S.

Wang

H. L.

Kip

K. E.

Meng

Park

J. Y.

(2018). Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors. Psycho-Oncology, 27(2), 524–531. https://doi.org/10.1002/pon.4491

30.

Liao

Y. J.

Jiang

J. R.

Jin

S. Q.

(2017). The association between COMT Val158Met polymorphism and migraine risk: A meta-analysis. Cephalalgia, 37(6), 592–598. https://doi.org/10.1177/0333102416649758

31.

Linschoten

Teske

A. J.

Cramer

M. J.

van der Wall

Asselbergs

F. W.

(2018). Chemotherapy-related cardiac dysfunction: A systematic review of genetic variants modulating individual risk. Circ Genom Precis Med, 11(1), Article e001753. https://doi.org/10.1161/CIRCGEN.117.001753

32.

Maj

D'Elia

Satz

Janssen

Zaudig

Uchiyama

Starace

Galderisi

Chervinsky

World Health Organization, Division of Mental Health/Global Programme on AIDS . (1993). Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. Archives of Clinical Neuropsychology, 8(2), 123–135.

33.

Marangi

Orteschi

Milano

Mancano

Zollino

(2013). Interstitial deletion of 3p22.3p22.2 encompassing ARPP21 and CLASP2 is a potential pathogenic factor for a syndromic form of intellectual disability: A co-morbidity model with additional copy number variations in a large family. American Journal of Medical Genetics, 161A(11), 2890–2893. https://doi.org/10.1002/ajmg.a.36257

34.

Marsh

McLeod

H. L.

(2007). Pharmacogenetics and oncology treatment for breast cancer. Expert Opinion on Pharmacotherapy, 8(2), 119–127. https://doi.org/10.1517/14656566.8.2.119

35.

Matsuzaka

C. T.

Christofolini

Ota

V. K.

Gadelha

Berberian

A. A.

Noto

Mazzotti

D. R.

Spindola

L. M.

Moretti

P. N.

Smith

M. A. C.

Melaragno

M. I.

Belangero

S. I.

Bressan

R. A.

(2017). Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. British Journal of Psychiatry, 39(4), 302–308. https://doi.org/10.1590/1516-4446-2016-1987

36.

Morandi

Bonnefond

Lobbens

Yengo

Miraglia Del Giudice

Grandone

Lévy-Marchal

Weill

Maffeis

Froguel

(2016). Associations between type 2 diabetes-related genetic scores and metabolic traits, in obese and normal-weight youths. Journal of Clinical Endocrinology & Metabolism, 101(11), 4244–4250. https://doi.org/10.1210/jc.2016-2432

37.

Morey

R. A.

Hariri

A. R.

Gold

A. L.

Hauser

M. A.

Munger

H. J.

Dolcos

McCarthy

(2011). Serotonin transporter gene polymorphisms and brain function during emotional distraction from cognitive processing in posttraumatic stress disorder. BMC Psychiatry, 11, 76. https://doi.org/10.1186/1471-244X-11-76

38.

Muench

Schwandt

Jung

Cortes

C. R.

Momenan

Lohoff

F. W.

(2018). The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence. Translational Psychiatry, 8(1), 131. https://doi.org/10.1038/s41398-018-0184-9

39.

Network

N. C. C.

(2022). National comprehesive cancer network 2022. https://www.nccn.org/

40.

Teo

S. M.

Yeo

H. L.

Shwe

Gan

Y. X.

Cheung

Y. T.

Foo

K. M.

Cham

M. T.

Lee

J. A.

Tan

Y. P.

Fan

Yong

W. S.

Preetha

Loh

W. J. K.

Koo

S. L.

Jain

Lee

G. E.

Wong

Dent

Chan

(2016). Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro-Oncology, 18(2), 244–251. https://doi.org/10.1093/neuonc/nov162

41.

Noble

E. P.

(2000). The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics, 1(3), 309–333. https://doi.org/10.1517/14622416.1.3.309

42.

Park

J. Y.

Lengacher

C. A.

Reich

R. R.

Alinat

C. B.

Ramesar

Paterson

C. L.

Pleasant

M. L.

Park

H. Y.

Kiluk

Han

Ismail-Khan

Kip

K. E.

(2019). Translational genomic research: The role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]). Transl Behav Med, 9(4), 693–702. https://doi.org/10.1093/tbm/iby061

43.

Park

J. Y.

Lengacher

C. A.

Reich

R. R.

Park

H. Y.

Whiting

Nguyen

A. T.

Rodríguez

Meng

Tinsley

Chauca

Gordillo-Casero

Wittenberg

Joshi

Lin

Ismail-Khan

Kiluk

J. V.

Kip

K. E.

(2022). Translational genomic research: The association between genetic profiles and cognitive functioning or cardiac function among breast cancer survivors completing chemotherapy. Biological Research For Nursing, 24(4), 433–447. https://doi.org/10.1177/10998004221094386

44.

Percival

George

Gyertson

Hamill

Fernandes

Davies

Rahman

Banerjee

(2016). The integration of BRCA testing into oncology clinics. British Journal of Nursing, 25(12), 690–694. https://doi.org/10.12968/bjon.2016.25.12.690

45.

Ponce

Perez-Gonzalez

Aragues

Palomo

Rodriguez-Jimenez

Jimenez-Arriero

M. A.

Hoenicka

(2009). The ANKK1 kinase gene and psychiatric disorders. Neurotoxicity Research, 16(1), 50–59. https://doi.org/10.1007/s12640-009-9046-9

46.

Pullens

M. J.

De Vries

Roukema

J. A.

(2010). Subjective cognitive dysfunction in breast cancer patients: A systematic review. Psycho-Oncology, 19(11), 1127–1138. https://doi.org/10.1002/pon.1673

47.

Reyes-Gibby

C. C.

Spitz

Kurzrock

Fisch

Bruera

Shete

(2008). Molecular epidemiology, cancer-related symptoms, and cytokines pathway. The Lancet Oncology, 9(8), 777–785. https://doi.org/10.1016/S1470-2045(08)70197-9

48.

Savitz

Hodgkinson

C. A.

Martin-Soelch

Shen

P. H.

Szczepanik

Nugent

A. C.

Herscovitch

Grace

A. A.

Goldman

Drevets

W. C.

(2013). DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. International Journal of Neuropsychopharmacology, 16(9), 2095–2101. https://doi.org/10.1017/S146114571300045X

49.

Schagen

S. B.

Muller

M. J.

Boogerd

Mellenbergh

G. J.

van Dam

F. S.

(2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98(23), 1742–1745. https://doi.org/10.1093/jnci/djj470

50.

Shi

Wang

X. S.

Shah

N. D.

Orlowski

R. Z.

Williams

L. A.

Mendoza

T. R.

Cleeland

C. S.

(2015). Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer, 121(7), 1138–1146. https://doi.org/10.1002/cncr.29154

51.

Siegel

R. L.

Giaquinto

A. N.

Jemal

(2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12–49. https://doi.org/10.3322/caac.21820

52.

Small

B. J.

Rawson

K. S.

Walsh

Jim

H. S.

Hughes

T. F.

Iser

Andrykowski

M. A.

Jacobsen

P. B.

(2011). Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer, 117(7), 1369–1376. https://doi.org/10.1002/cncr.25685

53.

Spiller

Jung

K. J.

Lee

J. Y.

Jee

S. H.

(2020). Precision medicine and cardiovascular health: Insights from mendelian randomization analyses. Korean Circ J, 50(2), 91–111. https://doi.org/10.4070/kcj.2019.0293

54.

T. T.

Azzani

Tan

F. L.

Loh

S. Y.

(2018). Breast cancer survivors: Return to work and wage loss in selected hospitals in Malaysia. Supportive Care in Cancer, 26(5), 1617–1624. https://doi.org/10.1007/s00520-017-3987-y

55.

Tao

Lin

Yan

Wang

Zhang

(2017). Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: A functional MRI study. European Journal of Cancer Care, 26(6). https://doi.org/10.1111/ecc.12553

56.

Trenerry

M. R.

Crosson

Deboe

Leber

W. R.

(1989). Stroop neuropsychological screening test manual: Psychological Assessment Resources.

57.

Von Ah

Habermann

Carpenter

J. S.

Schneider

B. L.

(2013). Impact of perceived cognitive impairment in breast cancer survivors. European Journal of Oncology Nursing, 17(2), 236–241. https://doi.org/10.1016/j.ejon.2012.06.002

58.

Wagner

L. I.

Sweet

Butt

Lai

J.-s.

Cella

(2009). Measuring patient self-reported cognitive function: Development of the functional assessment of cancer therapy-cognitive function instrument. Journal of Supportive Oncology, 7(6), W32–W39.

59.

Wang

Chen

Sun

Chen

Wang

Shi

(2018). Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. Am J Med Genet B Neuropsychiatr Genet, 177(1), 3–9. https://doi.org/10.1002/ajmg.b.32573

60.

Wechsler

(2008). Wechsler adult intelligence scale-fourth edition (WAIS-IV). NCS Pearson.

61.

Xuan

Gan

Huang

Wang

Jia

Chen

Cheng

(2017). Altered network efficiency of functional brain networks in patients with breast cancer after chemotherapy. Oncotarget, 8(62), 105648–105661. https://doi.org/10.18632/oncotarget.22358

62.

Yao

Ding

Y. Y.

Wang

Z. B.

J. M.

Hong

Pan

S. N.

(2015). Effect of gene polymorphism of COMT and OPRM1 on the preoperative pain sensitivity in patients with cancer. International Journal of Clinical and Experimental Medicine, 8(6), 10036–10039.

63.

Han

Miao

Hua

(2023). Using mindfulness-based stress reduction to relieve loneliness, anxiety, and depression in cancer patients: A systematic review and meta-analysis. Medicine (Baltimore), 102(37), Article e34917. https://doi.org/10.1097/MD.0000000000034917

64.

Yue

J. K.

Pronger

A. M.

Ferguson

A. R.

Temkin

N. R.

Sharma

Rosand

Sorani

M. D.

McAllister

T. W.

Barber

Winkler

E. A.

Burchard

E. G.

Lingsma

H. F.

Cooper

S. R.

Puccio

A. M.

Okonkwo

D. O.

Diaz-Arrastia

Manley

G. T.

COBRIT Investigators TRACK-TBI Investigators . (2015). Association of a common genetic variant within ANKK1 with six-month cognitive performance after traumatic brain injury. Neurogenetics, 16(3), 169–180. https://doi.org/10.1007/s10048-015-0437-1

65.

Yue

J. K.

Winkler

E. A.

Rick

J. W.

Burke

J. F.

McAllister

T. W.

S. S.

Burchard

E. G.

Rosand

Temkin

N. R.

Korley

F. K.

Sorani

M. D.

Ferguson

A. R.

Lingsma

H. F.

Sharma

Robinson

C. K.

Yuh

E. L.

Tarapore

P. E.

Wang

K. K. W.

TRACK-TBI Investigators . (2017). DRD2 C957T polymorphism is associated with improved 6-month verbal learning following traumatic brain injury. Neurogenetics, 18(1), 29–38. https://doi.org/10.1007/s10048-016-0500-6